These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 11160777)

  • 1. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC; Schneider EF; Fonseca VA
    Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all glitazones the same?
    Van Gaal L; Scheen AJ
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone in type II diabetes mellitus.
    Sparano N; Seaton TL
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Against insulin resistance. Insulin sensitizers].
    Verspohl EJ; Weiland F
    Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
    [No Abstract]   [Full Text] [Related]  

  • 9. New therapeutic approaches to reversing insulin resistance.
    Sonnenberg GE; Kotchen TA
    Curr Opin Nephrol Hypertens; 1998 Sep; 7(5):551-5. PubMed ID: 9818203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE; Banerji MA
    Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC
    Adv Drug Deliv Rev; 2002 Nov; 54(9):1173-97. PubMed ID: 12393300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where thiazolidinediones will fit.
    Reasner CA
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S30-5. PubMed ID: 11921436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
    Kudzma DJ
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
    Ginsberg H; Plutzky J; Sobel BE
    J Cardiovasc Risk; 1999 Oct; 6(5):337-46. PubMed ID: 10534139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Insulin sensitizer. A new therapy option for type 2 diabetic patients].
    Filz HP
    MMW Fortschr Med; 2000 Sep; 142(38):31-3. PubMed ID: 11050888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.